利奈唑胺单药q12h与q8h及联合达托霉素治疗实验性MRSA/GISA心内膜炎的疗效
该研究通过体外时间杀菌试验和实验性心内膜炎模型,评估利奈唑胺每12小时与每8小时给药及利奈唑胺q12h联合达托霉素对MRSA和GISA菌株的疗效。结果显示,对MRSA-277心内膜炎,利奈唑胺q8h与q12h活性相似(P=0.15);对GISA-700788心内膜炎,利奈唑胺q8h比利奈唑胺q12h更有效(P<0.001)。达托霉素单药分别灭菌70%和60%的瓣膜赘生物,联合利奈唑胺q12h分别为60%和56%,未见拮抗。
要点
- 对GISA-700788心内膜炎,利奈唑胺q8h比利奈唑胺q12h更有效(P<0.001)。
- 对MRSA-277心内膜炎,利奈唑胺q8h与q12h活性相似(P=0.15)。
- 达托霉素联合利奈唑胺q12h体外及体内均未显示拮抗,未恢复达托霉素不敏感菌株。
核心结论
- 增加利奈唑胺至600 mg/8 h可能作为临床实践中的初始治疗有用。
- 如有需要,达托霉素联合利奈唑胺q12h可能是MRSA/GISA菌血症/心内膜炎的合适选择。
研究设计与样本
- 体外时间杀菌试验使用标准(105 cfu/L)和高(109 cfu/mL)接种量的六株MRSA菌株(包括一株GISA菌株)。
- 选择MRSA-277和GISA-700788用于实验性心内膜炎模型,动物接受利奈唑胺q12h(600 mg/kg/12 h)、利奈唑胺q8h(600 mg/kg/8 h)、达托霉素(6 mg/kg/day)或达托霉素联合利奈唑胺q12h模拟人类血清水平。
主要发现
- 对MRSA-277实验性心内膜炎,利奈唑胺q8h与利奈唑胺q12h活性相似(P=0.15)。
- 对GISA-700788心内膜炎,利奈唑胺q8h比利奈唑胺q12h更有效(P<0.001)。
- 达托霉素单药对MRSA-277和GISA-700788实验性心内膜炎非常有效,分别灭菌70%和60%的瓣膜赘生物。
- 达托霉素联合利奈唑胺q12h分别灭菌60%和56%的瓣膜赘生物。
- 该联合体外和体内均未显示拮抗,未恢复达托霉素不敏感菌株。
临床怎么用
- 增加利奈唑胺至600 mg/8 h可能作为临床实践中的初始治疗有用。
- 如有需要,达托霉素联合利奈唑胺q12h可能是MRSA/GISA菌血症/心内膜炎的合适选择。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Daptomycin is a bactericidal antibiotic, highly effective against MRSA. Linezolid, though bacteriostatic, is effective in MRSA pneumonia and has excellent meningeal penetration. Therefore, the combination of both antibiotics can be required in some patients with disseminated MRSA infections. OBJECTIVES: This study aimed to evaluate the in vitro activity of linezolid plus daptomycin against MRSA and glycopeptide-intermediate Staphylococcus aureus (GISA) strains and to determine the efficacy of linezolid monotherapy administered every 12 h versus every 8 h versus the combination of linezolid-q12h plus daptomycin against MRSA and GISA experimental endocarditis (EE). METHODS: In vitro time-kill studies were performed using standard (105 cfu/L) and high (109 cfu/mL) inoculum of six MRSA strains, including one GISA strain. MRSA-277 and GISA-700788 were selected for the EE model. Animals were treated with linezolid-q12h (600 mg/kg/12 h), linezolid-q8h (600 mg/kg/8 h), daptomycin (6 mg/kg/day) or daptomycin plus linezolid-q12h mimicking human-like serum levels. RESULTS: Linezolid-q8h and linezolid-q12h showed similar activity in MRSA-277 EE (P = 0.15). Against GISA-700788 endocarditis, linezolid-q8h was more effective than linezolid-q12h (P < 0.001). Daptomycin monotherapy was very effective against MRSA-277 and GISA-700788 EE, sterilizing 70% and 60% of valvular vegetations, respectively. Daptomycin plus linezolid-q12h was similarly effective at 60% and 56%, respectively. This combination showed neither in vitro nor in vivo antagonism, and daptomycin-non-susceptible strains were not recovered. CONCLUSIONS: Increasing linezolid to 600 mg/8 h might be useful as initial treatment in clinical practice. If required, the combination of daptomycin plus linezolid-q12h could be a suitable option in MRSA/GISA bacteraemia/endocarditis.
引用
- Cañas MA, García-de-la-Mària C, García-González J, et al. Efficacy of linezolid in monotherapy q12h versus q8h versus combined with daptomycin in the treatment of experimental endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus strains. J Antimicrob Chemother. 2025. PMID: 40424179. doi:10.1093/jac/dkaf149
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。